The diabetes therapy, Jardiance (empagliflozin) is continuing to be a key driver of growth at the family-owned, Germany-headquartered Boehringer Ingelheim GmbH, with currency-adjusted net sales of €1.2bn in the first half of 2020, up by 22.7% compared with sales of around €1bn in the first half of 2019.
Boehringer Ingelheim is also continuing to support the use of empagliflozin in additional indications including its use in patients with heart failure – top-line data from the EMPEROR-Reduced outcomes trial released last week by Boehringer Ingelheim and its partner, Eli Lilly and Company, are expected to open up new market opportunities for the product
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?